Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $39.0 million.

  • 10x Genomics' Free Cash Flow rose 51208.79% to $39.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $130.1 million, marking a year-over-year increase of 237116.43%. This contributed to the annual value of $130.1 million for FY2025, which is 237116.43% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Free Cash Flow is $39.0 million, which was up 51208.79% from $42.5 million recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' Free Cash Flow peaked at $42.5 million during Q3 2025, and registered a low of -$48.9 million during Q1 2022.
  • Its 5-year average for Free Cash Flow is -$11.4 million, with a median of -$15.0 million in 2021.
  • Per our database at Business Quant, 10x Genomics' Free Cash Flow tumbled by 30306.9% in 2021 and then soared by 51208.79% in 2025.
  • Quarter analysis of 5 years shows 10x Genomics' Free Cash Flow stood at -$21.8 million in 2021, then fell by 19.25% to -$26.0 million in 2022, then soared by 185.76% to $22.3 million in 2023, then crashed by 142.42% to -$9.5 million in 2024, then surged by 512.09% to $39.0 million in 2025.
  • Its Free Cash Flow stands at $39.0 million for Q4 2025, versus $42.5 million for Q3 2025 and $16.1 million for Q2 2025.